603858 步长制药
2024/06 - 中期
人民幣(K¥)
与去年同期
比较
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
2021/12
人民幣(K¥)
2020/12
人民幣(K¥)
营业总收入5,431,672-21.93%13,245,13314,951,25315,762,68016,006,714
减:营业总成本5,064,719-19.36%12,225,17013,248,89014,146,14713,839,082
    其中:营业成本2,335,2367.18%4,218,2824,232,5104,132,7963,741,011
               财务费用59,37863.23%91,663113,527140,678118,143
               资产减值损失(22,291)135.70%(700,722)(3,035,204)(138,650)2,259
公允价值变动收益(2,953)-350.70%(2,356)--(60,000)--
投资收益3,224-83.36%21,2932,73517,61415,618
    其中:对联营企业和合营企业的投资收益5,034-38.40%10,301(1,115)12,60112,289
营业利润409,579-53.32%436,019(1,249,459)1,620,5742,365,365
利润总额403,973-53.26%394,557(1,259,389)1,586,5692,360,693
减:所得税费用222,83823.32%242,692331,594478,288517,551
净利润181,135-73.50%151,865(1,590,983)1,108,2811,843,142
减:非控股权益(50,281)-19.62%(167,108)(61,239)(53,837)(17,752)
股东净利润231,417-68.98%318,973(1,529,744)1,162,1181,860,894

市场价值指针
每股收益 (元) *0.211-68.72%0.288-1.3831.0511.683
每股派息 (元) *----0.1260.9600.3600.526
每股净资产 (元) *10.206-6.29%10.50311.17712.52412.014
审计意见 #--标准无保留意见标准无保留意见标准无保留意见标准无保留意见
回页顶
备注: *未调整数据
#只提供简体内容